Want to see LTRN full AI Analyst Report?

Lantern Pharma (LTRN) Earnings Dates, Call Summary & Reports

337 Followers

Earnings Data

Report Date

Aug 12, 2026

Before Open (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

-0.38

Last Year’s EPS

-0.4

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 1 Analysts Ratings

Earnings Call Summary

Q3 2025

Earnings Call Date:Nov 13, 2025|

% Change Since:

Earnings Call Sentiment|Positive

The earnings call highlighted significant achievements in clinical trial results and regulatory progress, along with advancements in AI platform commercialization. Financial stability was noted, but there is a requirement for additional funding in the near future.

Company Guidance

During Lantern Pharma's third quarter 2025 earnings call, the company highlighted several key metrics and milestones, signaling a transformative period. The LP-184 Phase Ia clinical trial achieved all primary endpoints with a 48% clinical benefit rate in cancer patients, particularly those with DNA damage repair mutations. The company also advanced its AI platform, RADR, and outlined future plans for its CNS-focused subsidiary, Starlight Therapeutics. Financially, Lantern reported a net loss of $4.2 million, or $0.39 per share, for the quarter, with $12.4 million in cash and equivalents, providing runway until the third quarter of 2026. The company also discussed its strategic approach to drug development, leveraging AI to identify high-probability success areas, and detailed upcoming clinical trials targeting a combined market opportunity exceeding $7 billion.

Successful LP-184 Phase Ia Clinical Trial

The LP-184 Phase Ia clinical trial successfully achieved all primary endpoints, demonstrating a 48% clinical benefit rate in evaluable cancer patients who received doses at or above the therapeutic threshold.

Regulatory Progress with FDA

Completed a productive FDA Type C meeting for Starlight Therapeutics, gaining clear guidance for a planned pediatric CNS cancer trial targeting ATRT.

Expansion of AI Platform, RADR

Demonstrated commercial readiness of the RADR AI platform with several deployable, scalable modules, indicating potential for significant revenue generation.

Financial Stability

As of September 30, 2025, Lantern Pharma had $12.4 million in cash, cash equivalents, and marketable securities, providing a runway into Q3 2026.

Positive Preliminary Data from LP-300 HARMONIC Trial

Preliminary data showed an 86% clinical benefit rate, with one patient demonstrating a durable complete response lasting nearly two years.

AI Platform Commercial Opportunities

Showcased commercial readiness of AI modules at the AI Biology and Medicine Symposium, highlighting potential revenue streams from licensing to biopharma partners.

Lantern Pharma (LTRN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LTRN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Play Transcript
Aug 12, 2026	2026 (Q2)	-0.38 / -	-0.4	―	―
May 15, 2026	2026 (Q1)	-0.36 / -0.30	-0.42	28.57% (+0.12)	―
Mar 30, 2026	2025 (Q4)	-0.46 / -0.36	-0.54	33.33% (+0.18)
Nov 13, 2025	2025 (Q3)	-0.47 / -0.39	-0.42	7.14% (+0.03)
Aug 13, 2025	2025 (Q2)	-0.44 / -0.40	-0.46	13.04% (+0.06)	―
May 15, 2025	2025 (Q1)	-0.49 / -0.42	-0.51	17.65% (+0.09)
Mar 27, 2025	2024 (Q4)	-0.51 / -0.54	-0.39	-38.46% (-0.15)
Nov 07, 2024	2024 (Q3)	-0.56 / -0.42	-0.29	-44.83% (-0.13)
Aug 08, 2024	2024 (Q2)	-0.55 / -0.46	-0.44	-4.55% (-0.02)
May 09, 2024	2024 (Q1)	-0.43 / -0.51	-0.36	-41.67% (-0.15)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LTRN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 15, 2026	$3.14	$3.00	-4.46%
Mar 30, 2026	$1.24	$1.37	+10.93%
Nov 13, 2025	$3.48	$3.46	-0.57%
Aug 13, 2025	$4.76	$4.57	-3.99%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lantern Pharma, Inc. (LTRN) report earnings?

Lantern Pharma, Inc. (LTRN) is schdueled to report earning on Aug 12, 2026, Before Open (Confirmed).

What is Lantern Pharma, Inc. (LTRN) earnings time?

Lantern Pharma, Inc. (LTRN) earnings time is at Aug 12, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LTRN EPS forecast?

LTRN EPS forecast for the fiscal quarter 2026 (Q2) is -0.38.